Bonnie Ch Kwan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/833968/publications.pdf

Version: 2024-02-01

163 papers 5,890 citations

57758 44 h-index 91884 69 g-index

163 all docs

163 docs citations

163 times ranked 6080 citing authors

#	Article	IF	CITATIONS
1	Predictors and prognostic significance of persistent fluid overload: A longitudinal study in Chinese peritoneal dialysis patients. Peritoneal Dialysis International, 2023, 43, 252-262.	2.3	4
2	Adipose expression of miR-130b and miR-17-5p with wasting, cardiovascular event and mortality in advanced chronic kidney disease patients. Nephrology Dialysis Transplantation, 2022, 37, 1935-1943.	0.7	8
3	Adipose and serum zinc alpha-2-glycoprotein (ZAG) expressions predict longitudinal change of adiposity, wasting and predict survival in dialysis patients. Scientific Reports, 2022, 12, .	3.3	4
4	Depression does not predict clinical outcome of Chinese peritoneal Dialysis patients after adjusting for the degree of frailty. BMC Nephrology, 2020, 21, 329.	1.8	9
5	Longitudinal Changes of NF-κB Downstream Mediators and Peritoneal Transport Characteristics in Incident Peritoneal Dialysis Patients. Scientific Reports, 2020, 10, 6440.	3.3	8
6	Relationship between Plasma Endocan Level and Clinical Outcome of Chinese Peritoneal Dialysis Patients. Kidney and Blood Pressure Research, 2019, 44, 1259-1270.	2.0	18
7	Clinical practice guidelines for the provision of renal service in Hong Kong: Accreditation of Renal Unit. Nephrology, 2019, 24, 130-132.	1.6	1
8	Urinary miRNA profile for the diagnosis of IgA nephropathy. BMC Nephrology, 2019, 20, 77.	1.8	26
9	The efficacy of managing fluid overload in chronic peritoneal dialysis patients by a structured nurse-led intervention protocol. BMC Nephrology, 2019, 20, 454.	1.8	4
10	Peritoneal protein clearance predicts mortality in peritoneal dialysis patients. Clinical and Experimental Nephrology, 2019, 23, 551-560.	1.6	20
11	Peritoneal Dialysis Catheter Revision and Replacement by Nephrologist for Peritoneal Dialysis Catheter Malfunction. Nephron, 2018, 138, 214-219.	1.8	103
12	Urinary mitochondrial DNA level is an indicator of intra-renal mitochondrial depletion and renal scarring in diabetic nephropathy. Nephrology Dialysis Transplantation, 2018, 33, 784-788.	0.7	49
13	Causes of nephrotic syndrome and nephroticâ€range proteinuria are different in adult Chinese patients: A single centre study over 33Âyears. Nephrology, 2018, 23, 565-572.	1.6	14
14	The choice of comorbidity scoring system in Chinese peritoneal dialysis patients. Clinical and Experimental Nephrology, 2018, 22, 159-166.	1.6	7
15	Urinary mitochondrial DNA level as a biomarker of tissue injury in non-diabetic chronic kidney diseases. BMC Nephrology, 2018, 19, 367.	1.8	18
16	Urinary mitochondrial DNA level in non-diabetic chronic kidney diseases. Clinica Chimica Acta, 2018, 484, 36-39.	1.1	23
17	Asymptomatic fluid overload predicts survival and cardiovascular event in incident Chinese peritoneal dialysis patients. PLoS ONE, 2018, 13, e0202203.	2.5	38
18	Depression and Physical Frailty Have Additive Effect on the Nutritional Status and Clinical Outcome of Chinese Peritoneal Dialysis. Kidney and Blood Pressure Research, 2018, 43, 914-923.	2.0	25

#	Article	IF	CITATIONS
19	Peritoneal dialysis-related peritonitis caused by Pseudomonas species: Insight from a post-millennial case series. PLoS ONE, 2018, 13, e0196499.	2.5	17
20	Characteristics and clinical outcomes of living renal donors in Hong Kong. Hong Kong Medical Journal, 2018, 24, 11-17.	0.1	2
21	Peritoneal inflammation and fibrosis in Câ€reactive protein transgenic mice undergoing peritoneal dialysis solution treatment. Nephrology, 2017, 22, 125-132.	1.6	4
22	Manifestation of tranexamic acid toxicity in chronic kidney disease and kidney transplant patients: A report of four cases and review of literature. Nephrology, 2017, 22, 316-321.	1.6	19
23	Therapeutic drug monitoring of onceâ€daily tacrolimus (Advagraf) in a gastrectomized kidney transplant recipient. Nephrology, 2017, 22, 184-184.	1.6	0
24	Peritoneal dialysis effluent miR-21 and miR-589 levels correlate with longitudinal change in peritoneal transport characteristics. Clinica Chimica Acta, 2017, 464, 106-112.	1.1	11
25	Treatment of Enterococcal Peritonitis in Peritoneal Dialysis Patients by Oral Amoxicillin or Intra-Peritoneal Vancomcyin: a Retrospective Study. Kidney and Blood Pressure Research, 2017, 42, 837-843.	2.0	11
26	Urinary Mitochondrial DNA Level as a Biomarker of Acute Kidney Injury Severity. Kidney Diseases (Basel,) Tj ETQq	0 0 0 rgBT	·/Qverlock 10
27	Frailty in Chinese Peritoneal Dialysis Patients: Prevalence and Prognostic Significance. Kidney and Blood Pressure Research, 2016, 41, 736-745.	2.0	30
28	Urinary sediment mRNA level of extracellular matrix molecules in adult nephrotic syndrome. Clinica Chimica Acta, 2016, 456, 157-162.	1.1	7
29	Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis. CKJ: Clinical Kidney Journal, 2016, 9, 616-623.	2.9	14
30	Dialysate bacterial endotoxin as a prognostic indicator of peritoneal dialysis related peritonitis. Nephrology, 2016, 21, 1069-1072.	1.6	9
31	Peritonitis before Peritoneal Dialysis Training: Analysis of Causative Organisms, Clinical Outcomes, Risk Factors, and Long-Term Consequences. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1219-1226.	4.5	15
32	Plasma Mitochondrial DNA Level is a Prognostic Marker in Peritoneal Dialysis Patients. Kidney and Blood Pressure Research, 2016, 41, 402-412.	2.0	9
33	Menstrual loss of renal function: a case of mefenamic acid induced renal cortical necrosis. Clinical Nephrology, 2016, 86, 162-164.	0.7	1
34	Urinary mRNA levels of ELRâ€negative CXC chemokine ligand and extracellular matrix in diabetic nephropathy. Diabetes/Metabolism Research and Reviews, 2015, 31, 699-706.	4.0	17
35	Predictors of Residual Renal Function Decline in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis. Peritoneal Dialysis International, 2015, 35, 180-188.	2.3	65
36	Functional and histological improvement after everolimus rescue of chronic allograft dysfunction in renal transplant recipients. Therapeutics and Clinical Risk Management, 2015, 11, 829.	2.0	4

#	Article	IF	CITATIONS
37	Circulating Bacterial-Derived DNA Fragment Level Is a Strong Predictor of Cardiovascular Disease in Peritoneal Dialysis Patients. PLoS ONE, 2015, 10, e0125162.	2.5	31
38	The Effect of Neutral Peritoneal Dialysis Solution with Low Glucose-Degradation-Product on the Fluid Status and Body Composition – A Randomized Control Trial. PLoS ONE, 2015, 10, e0141425.	2.5	17
39	Intrarenal and Urinary Th9 and Th22 Cytokine Gene Expression in Lupus Nephritis. Journal of Rheumatology, 2015, 42, 1150-1155.	2.0	14
40	Weight change during the first year of peritoneal dialysis: Risk factors and prognostic implications. Hong Kong Journal of Nephrology, 2015, 17, 28-35.	0.0	8
41	Long-term Outcome of Biopsy-Proven Minimal Change Nephropathy in Chinese Adults. American Journal of Kidney Diseases, 2015, 65, 710-718.	1.9	35
42	Podocyte mRNA in the urinary sediment of minimal change nephropathy and focal segmental glomerulosclerosis. Clinical Nephrology, 2015, 84 (2015), 198-205.	0.7	9
43	Bioimpedance Spectroscopy for the Detection of Fluid Overload in Chinese Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2014, 34, 409-416.	2.3	60
44	Metabolic Syndrome in Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 779-787.	4.5	23
45	Randomized controlled study of icodextrin on the treatment of peritoneal dialysis patients during acute peritonitis. Nephrology Dialysis Transplantation, 2014, 29, 1438-1443.	0.7	24
46	Effect of cinacalcet treatment on vascular arterial stiffness among peritoneal dialysis patients with secondary hyperparathyroidism. Nephrology, 2014, 19, 339-344.	1.6	8
47	Relationship between HSP70-2 A+1267G Polymorphism and Cardiovascular Events of Chinese Peritoneal Dialysis Patients. Nephron Clinical Practice, 2014, 128, 153-158.	2.3	3
48	Peritonealâ€dialysis related peritonitis caused by <i><scp>G</scp>ordonia</i> species: Report of four cases and literature review. Nephrology, 2014, 19, 379-383.	1.6	17
49	Clinical manifestation of macrolide antibiotic toxicity in CKD and dialysis patients. CKJ: Clinical Kidney Journal, 2014, 7, 507-512.	2.9	26
50	Public lacks knowledge on chronic kidney disease: telephone survey. Hong Kong Medical Journal, 2014, 20, 139-44.	0.1	40
51	Urinary mRNA in Systemic Lupus Erythematosus. Advances in Clinical Chemistry, 2013, 62, 197-219.	3.7	4
52	Spurious hypernatraemia. Nephrology, 2013, 18, 531-532.	1.6	0
53	Treatment of Early Immunoglobulin A Nephropathy by Angiotensin-converting Enzyme Inhibitor. American Journal of Medicine, 2013, 126, 162-168.	1.5	24
54	Urinary sediment miRNA levels in adult nephrotic syndrome. Clinica Chimica Acta, 2013, 418, 5-11.	1.1	49

#	Article	IF	Citations
55	Long-term outcome of biopsy-proven minimal-change nephrotic syndrome in Chinese children. Hong Kong Journal of Nephrology, 2013, 15, 22-27.	0.0	4
56	Bacteria-Derived DNA Fragment in Peritoneal Dialysis Effluent as a Predictor of Relapsing Peritonitis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1935-1941.	4.5	31
57	Circulating bacterial-derived DNA fragments as a marker * of systemic inflammation in peritoneal dialysis. Nephrology Dialysis Transplantation, 2013, 28, 2139-2145.	0.7	35
58	Predicting 12-Month Mortality for Peritoneal Dialysis Patients Using the "Surprise―Question. Peritoneal Dialysis International, 2013, 33, 60-66.	2.3	45
59	Campylobacter Peritonitis Complicating Peritoneal Dialysis: A Review of 12 Consecutive Cases. Peritoneal Dialysis International, 2013, 33, 189-194.	2.3	4
60	Effect of Using Ultrapure Dialysate for Hemodialysis on the Level of Circulating Bacterial Fragment in Renal Failure Patients. Nephron Clinical Practice, 2013, 123, 246-253.	2.3	18
61	Automated peritoneal dialysis in <scp>H</scp> ong <scp>K</scp> ong: There are two distinct groups of patients. Nephrology, 2013, 18, 356-364.	1.6	15
62	The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy – A Randomized Cross-Over Study. PLoS ONE, 2013, 8, e62736.	2.5	19
63	Hypokalaemia and cardiac risk in peritoneal dialysis patients. Nature Reviews Nephrology, 2012, 8, 501-503.	9.6	10
64	Relationship of Intrarenal Gene Expression and the Histological Class of Lupus Nephritis — A Study on Repeat Renal Biopsy. Journal of Rheumatology, 2012, 39, 1942-1947.	2.0	13
65	Urinary sediment ICAM-1 level in lupus nephritis. Lupus, 2012, 21, 1190-1195.	1.6	38
66	Relationship betweenCRPPolymorphism and Cardiovascular Events in Chinese Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 304-309.	4.5	11
67	Relationship between Myeloid-Related Protein 8/14 and Survival of Chinese Peritoneal Dialysis Patients. Kidney and Blood Pressure Research, 2012, 35, 489-496.	2.0	4
68	Urinary miR-21, miR-29, and miR-93: Novel Biomarkers of Fibrosis. American Journal of Nephrology, 2012, 36, 412-418.	3.1	130
69	Monitoring of urinary messenger RNA levels for the prediction of flare in systemic lupus erythematosus. Clinica Chimica Acta, 2012, 413, 448-455.	1.1	13
70	Relation between MicroRNA Expression in Peritoneal Dialysis Effluent and Peritoneal Transport Characteristics. Disease Markers, 2012, 33, 35-42.	1.3	16
71	Prognostic Value of Arterial Pulse Wave Velocity in Peritoneal Dialysis Patients. American Journal of Nephrology, 2012, 35, 127-133.	3.1	39
72	Expression of microRNAs in the Urine of Patients With Bladder Cancer. Clinical Genitourinary Cancer, 2012, 10, 106-113.	1.9	134

#	Article	IF	Citations
73	Laparoscopic live donor nephrectomy: Current practice and results of renal transplantation. Surgical Practice, 2012, 16, 17-21.	0.2	0
74	Glomerular and tubulointerstitial miRâ€638, miRâ€198 and miRâ€146a expression in lupus nephritis. Nephrology, 2012, 17, 346-351.	1.6	99
75	Relationship between serum levels of tumour necrosis factorâ€related apoptosisâ€inducing ligand and the survival of Chinese peritoneal dialysis patients. Nephrology, 2012, 17, 466-471.	1.6	4
76	Cross sectional survey on the concerns and anxiety of patients waiting for organ transplants. Nephrology, 2012, 17, 514-518.	1.6	18
77	Fracture risk after thiazideâ€associated hyponatraemia. Internal Medicine Journal, 2012, 42, 760-764.	0.8	13
78	Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus. Clinical Rheumatology, 2012, 31, 435-440.	2.2	77
79	Relation between microRNA expression in peritoneal dialysis effluent and peritoneal transport characteristics. Disease Markers, 2012, 33, 35-42.	1.3	9
80	Relationship between glutathione S-transferase M1 polymorphism and clinical outcomes in Chinese peritoneal dialysis patients. Journal of Nephrology, 2012, 25, 310-316.	2.0	2
81	Gene expression of TWEAK/Fn14 and IPâ€10/CXCR3 in glomerulus and tubulointerstitium of patients with lupus nephritis. Nephrology, 2011, 16, 426-432.	1.6	50
82	Life expectancy of Chinese patients with chronic kidney disease without dialysis. Nephrology, 2011, 16, 715-719.	1.6	13
83	Peritoneal Dialysis as the First-line Renal Replacement Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease. American Journal of Kidney Diseases, 2011, 57, 903-907.	1.9	66
84	Serum and urinary free microRNA level in patients with systemic lupus erythematosus. Lupus, 2011, 20, 493-500.	1.6	142
85	Haemoglobin variability in Chinese pre-dialysis CKD patients not receiving erythropoietin. Nephrology Dialysis Transplantation, 2011, 26, 2919-2924.	0.7	5
86	Repeat Peritonitis in Peritoneal Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 827-833.	4.5	30
87	Persistent Symptomatic Intra-Abdominal Collection after Catheter Removal for Pd-Related Peritonitis. Peritoneal Dialysis International, 2011, 31, 34-38.	2.3	12
88	Repeat Renal Biopsy in Lupus Nephritis: A Change in Histological Pattern Is Common. American Journal of Nephrology, 2011, 34, 220-225.	3.1	39
89	Expression of ACE and ACE2 in Patients with Hypertensive Nephrosclerosis. Kidney and Blood Pressure Research, 2011, 34, 141-149.	2.0	28
90	Elevated Levels of miR-146a and miR-155 in Kidney Biopsy and Urine from Patients with IgA Nephropathy. Disease Markers, 2011, 30, 171-179.	1.3	109

#	Article	IF	CITATIONS
91	Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. Disease Markers, 2011, 30, 171-9.	1.3	85
92	Measurements on the routine chest radiograph as prognostic markers in Chinese peritoneal dialysis patients. Clinical Nephrology, 2011, 76, 16-22.	0.7	8
93	Is peritoneal dialysis kinder for the heart?. Peritoneal Dialysis International, 2011, 31, 135-7.	2.3	3
94	Serum and Urinary Cell–free MiR-146a and MiR-155 in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2010, 37, 2516-2522.	2.0	174
95	Intrarenal expression of microRNAs in patients with IgA nephropathy. Laboratory Investigation, 2010, 90, 98-103.	3.7	103
96	Relationship between $\hat{l}^21\hat{a}$ eadrenergic receptor polymorphisms and cardiovascular disease in patients with diabetic nephropathy. Nephrology, 2010, 15, 242-247.	1.6	2
97	Expression of MicroRNAs in the Urinary Sediment of Patients with IgA Nephropathy. Disease Markers, 2010, 28, 79-86.	1.3	93
98	Effect of Membrane Permeability on Inflammation and Arterial Stiffness. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 652-658.	4.5	23
99	Endotoxemia is Associated with Better Clinical Outcome in Incident Chinese Peritoneal Dialysis Patients: A Prospective Cohort Study. Peritoneal Dialysis International, 2010, 30, 178-186.	2.3	21
100	Unexplained Exudative Pleural Effusion in Chronic Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2010, 30, 534-540.	2.3	13
101	Tenckhoff Catheter Insertion by Nephrologists: Open Dissection Technique. Peritoneal Dialysis International, 2010, 30, 524-527.	2.3	26
102	Outcome of Hemodialysis Patients Who Had Failed Peritoneal Dialysis. Nephron Clinical Practice, 2010, 116, c300-c306.	2.3	14
103	Arterial Pulse Wave Velocity and Peritoneal Transport Characteristics Independently Predict Hospitalization in Chinese Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2010, 30, 80-85.	2.3	12
104	Intrarenal Expression of miRNAs in Patients With Hypertensive Nephrosclerosis. American Journal of Hypertension, 2010, 23, 78-84.	2.0	107
105	Extra-high-dose hepatitis B vaccination does not confer longer serological protection in peritoneal dialysis patients: a randomized controlled trial. Nephrology Dialysis Transplantation, 2010, 25, 2303-2309.	0.7	15
106	Urinary Expression of Kidney Injury Markers in Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2329-2337.	4.5	44
107	The width of the basement membrane does not influence clinical presentation or outcome of thin glomerular basement membrane disease with persistent hematuria. Kidney International, 2010, 78, 1041-1046.	5.2	9
108	Geriatric Nutritional Risk Index as a Screening Tool for Malnutrition in Patients on Chronic Peritoneal Dialysis., 2010, 20, 29-37.		41

#	Article	IF	CITATIONS
109	Intra-renal and urinary mRNA expression of podocyte-associated molecules for the estimation of glomerular podocyte loss. Renal Failure, 2010, 32, 372-379.	2.1	19
110	Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Disease Markers, 2010, 28, 79-86.	1.3	71
111	Factors Associated with Sudden Death in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2009, 29, 58-63.	2.3	8
112	Treatment of Metabolic Syndrome in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2009, 29, 149-152.	2.3	24
113	The gene expression of type 17 T-helper cell-related cytokines in the urinary sediment of patients with systemic lupus erythematosus. Rheumatology, 2009, 48, 1491-1497.	1.9	79
114	Longitudinal Changes of Cardiothoracic Ratio and Vascular Pedicle Width as Predictors of Volume Status during One Year in Chinese Peritoneal Dialysis Patients. Kidney and Blood Pressure Research, 2009, 32, 45-50.	2.0	16
115	Discrepancy between Intrarenal Messenger RNA and Protein Expression of ACE and ACE2 in Human Diabetic Nephropathy. American Journal of Nephrology, 2009, 29, 524-531.	3.1	39
116	Podocyte Loss in Human Hypertensive Nephrosclerosis. American Journal of Hypertension, 2009, 22, 300-306.	2.0	79
117	Urinary FOXP3 mRNA in patients with lupus nephritis-relation with disease activity and treatment response. Rheumatology, 2009, 48, 755-760.	1.9	29
118	Recurrent and Relapsing Peritonitis: Causative Organisms and Response to Treatment. American Journal of Kidney Diseases, 2009, 54, 702-710.	1.9	62
119	Serial monitoring of nutritional status in Chinese peritoneal dialysis patients by Subjective Global Assessment and comprehensive Malnutrition Inflammation Score. Nephrology, 2009, 14, 143-147.	1.6	11
120	Association of interleukinâ€18 promoter polymorphism and atherosclerotic diseases in Chinese patients with diabetic nephropathy. Nephrology, 2009, 14, 606-612.	1.6	12
121	Fatal Pancytopenia in a Hemodialysis Patient After Treatment With Low-Dose Methotrexate. Journal of Clinical Rheumatology, 2009, 15, 177-180.	0.9	25
122	Treatment of metabolic syndrome in peritoneal dialysis patients. Peritoneal Dialysis International, 2009, 29 Suppl 2, S149-52.	2.3	15
123	Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy. Diabetologia, 2008, 51, 1062-1067.	6.3	47
124	Oral Calcitriol for the Treatment of Persistent Proteinuria in Immunoglobulin A Nephropathy: An Uncontrolled Trial. American Journal of Kidney Diseases, 2008, 51, 724-731.	1.9	87
125	In Reply To â€~The Beneficial Effect of Oral Calcitriol Treatment on Proteinuria in IgA Nephropathy: Another Point of View'. American Journal of Kidney Diseases, 2008, 52, 805.	1.9	3
126	Relationship Between \hat{l}^21 -Adrenergic Receptor Polymorphisms and Cardiovascular Disease in Peritoneal Dialysis Patients. Hong Kong Journal of Nephrology, 2008, 10, 58-63.	0.0	2

#	Article	IF	CITATIONS
127	Peroxisome Proliferator-Activated Receptor-Gamma Gene Polymorphism and Risk of Cardiovascular Disease in Patients with Diabetic Nephropathy. American Journal of Nephrology, 2008, 28, 715-722.	3.1	19
128	Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology, 2008, 47, 1678-1681.	1.9	115
129	Metabolic syndrome in peritoneal dialysis patients. CKJ: Clinical Kidney Journal, 2008, 1, 206-214.	2.9	10
130	Coagulase Negative Staphylococcal Peritonitis in Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 91-97.	4.5	57
131	Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker. European Journal of Endocrinology, 2008, 158, 317-322.	3.7	42
132	Endotoxemia is Related to Systemic Inflammation and Atherosclerosis in Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 431-436.	4.5	177
133	The relationship between bone morphogenic protein-7 and peritoneal transport characteristics. Nephrology Dialysis Transplantation, 2008, 23, 2989-2994.	0.7	4
134	Impact of Early Nephrology Referral on Mortality and Hospitalization in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2008, 28, 371-376.	2.3	22
135	Staphylococcus aureus Peritonitis Complicates Peritoneal Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 245-251.	4.5	94
136	Increased subcutaneous insulin requirements in diabetic patients recently commenced on peritoneal dialysis. Nephrology Dialysis Transplantation, 2007, 22, 1697-1702.	0.7	20
137	Cellular and morphological changes during neointimal hyperplasia development in a porcine arteriovenous graft model. Nephrology Dialysis Transplantation, 2007, 22, 3139-3146.	0.7	64
138	Associations of Body Size with Metabolic Syndrome and Mortality in Moderate Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 992-998.	4.5	60
139	Carotid Intima Media Thickness Predicts Cardiovascular Diseases in Chinese Predialysis Patients with Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 1966-1972.	6.1	85
140	Lipoprotein Metabolism and Lipid Management in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 1246-1261.	6.1	280
141	SUCCESSFUL EMBOLIZATION OF TRANSPLANT KIDNEY ARTERIOVENOUS FISTULA. Nephrology, 2007, 12, 623-624.	1.6	0
142	CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: A Story Half Untold: Adiposity, Adipokines and Outcomes in Dialysis Population. Seminars in Dialysis, 2007, 20, 493-497.	1.3	19
143	New-Onset Hyperglycemia in Nondiabetic Chinese Patients Started on Peritoneal Dialysis. American Journal of Kidney Diseases, 2007, 49, 524-532.	1.9	94
144	Connective Tissue Growth Factor Is Responsible for Transforming Growth Factor-Beta-Induced Peritoneal Mesothelial Cell Apoptosis. Nephron Experimental Nephrology, 2006, 103, e166-e174.	2.2	19

#	Article	IF	Citations
145	Influence of climate on the incidence of thiazide-induced hyponatraemia. International Journal of Clinical Practice, 2006, 61, 449-452.	1.7	13
146	Enterobacteriaceae peritonitis complicating peritoneal dialysis: A review of 210 consecutive cases. Kidney International, 2006, 69, 1245-1252.	5. 2	102
147	mRNA Expression of Target Genes in the Urinary Sediment as a Noninvasive Prognostic Indicator of CKD. American Journal of Kidney Diseases, 2006, 47, 578-586.	1.9	25
148	Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products—A 1-year randomized control trial. Nephrology Dialysis Transplantation, 2006, 22, 552-559.	0.7	152
149	Adherence to peritoneal dialysis training schedule. Nephrology Dialysis Transplantation, 2006, 22, 545-551.	0.7	14
150	Change in bacterial aetiology of peritoneal dialysis-related peritonitis over 10 years: experience from a centre in south-east Asia. Clinical Microbiology and Infection, 2005, 11, 837-839.	6.0	70
151	Prevalence of silent kidney disease in Hong Kong: The Screening for Hong Kong Asymptomatic Renal Population and Evaluation (SHARE) program. Kidney International, 2005, 67, S36-S40.	5.2	44
152	Hypokalemia in Chinese Peritoneal Dialysis Patients: Prevalence and Prognostic Implication. American Journal of Kidney Diseases, 2005, 46, 128-135.	1.9	84
153	A Risk Analysis of Continuous Ambulatory Peritoneal Dialysis-Related Peritonitis. Peritoneal Dialysis International, 2005, 25, 374-379.	2.3	127
154	Peritoneal Albumin Excretion is a Strong Predictor of Cardiovascular Events in Peritoneal Dialysis Patients: A Prospective Cohort Study. Peritoneal Dialysis International, 2005, 25, 445-452.	2.3	46
155	The clinical course of peritoneal dialysis-related peritonitis caused by Corynebacterium species. Nephrology Dialysis Transplantation, 2005, 20, 2793-2796.	0.7	27
156	A risk analysis of continuous ambulatory peritoneal dialysis-related peritonitis. Peritoneal Dialysis International, 2005, 25, 374-9.	2.3	66
157	Peritoneal albumin excretion is a strong predictor of cardiovascular events in peritoneal dialysis patients: a prospective cohort study. Peritoneal Dialysis International, 2005, 25, 445-52.	2.3	28
158	Cefazolin plus Ceftazidime versus Imipenem / Cilastatin Monotherapy for Treatment of Capd Peritonitis — a Randomized Controlled Trial. Peritoneal Dialysis International, 2004, 24, 440-446.	2.3	37
159	Severe Acute Respiratory Syndrome in Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2004, 15, 1883-1888.	6.1	54
160	Asymptomatic isolated microscopic haematuria: long-term follow-up. QJM - Monthly Journal of the Association of Physicians, 2004, 97, 739-745.	0.5	46
161	Cefazolin plus ceftazidime versus imipenem/cilastatin monotherapy for treatment of CAPD peritonitisa randomized controlled trial. Peritoneal Dialysis International, 2004, 24, 440-6.	2.3	17
162	Severe acute respiratory syndrome in a hemodialysis patient. American Journal of Kidney Diseases, 2003, 42, 1069-1074.	1.9	17

#	Article	IF	CITATIONS
163	Muscle infarction in peritoneal dialysis patients 11 Editor Note: The corresponding author declined to respond American Journal of Kidney Diseases, 2003, 42, 1102-1103.	1.9	1